Compared with antibodies targeting VEGF alone and antibodies targeting DLL4 alone, ABL001 has shown higher potency anticancer effects in several human cancer xenograft models (116, 117), and is currently being evaluated in a phase 1 clinical study of heavy chemotherapy or targeted therapy pre-treated cancer patients (118). The gene discussed is DLL4; the disease is cancer.